Assessment of the combination of doripenem plus a fluoroquinolone against nonsusceptible Acinetobacter baumannii isolates from nosocomial pneumonia patients

Journal of Chemotherapy

Volumn 25, Issue 3, 2013, Pages 141-147

  Queenan, Anne Marie ^a   Davies, Todd A ^a   He, Wenping ^a   Lynch, Anthony S ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Acinetobacter baumannii; Antibiotic combinations; Doripenem; Fluoroquinolone; In vivo synergy; Resistance

Indexed keywords

AMIKACIN; CARBAPENEM; CARBAPENEMASE; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; DORIPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ACINETOBACTER BAUMANNII; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DRUG EFFICACY; DRUG POTENTIATION; GENE MUTATION; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; PULSED FIELD GEL ELECTROPHORESIS; SEPTICEMIA; SURVIVAL;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; CARBAPENEMS; CIPROFLOXACIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; MICE; OFLOXACIN; PNEUMONIA, VENTILATOR-ASSOCIATED; RANDOM ALLOCATION; SURVIVAL ANALYSIS;

EID: 84878304079     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947813Y.0000000074     Document Type: Article

References (30)

1. Peleg AY, Seifert H, Paterson D. Acinetobacter baumannii: emergence of a successful pathogen. Clin Micro Rev. 2008;21: 538-82.
2. Gaynes R, Edwards JR; National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by Gram-negative bacilli. Clin Infect Dis. 2005;41:848-54.
3. Falagas ME, Karveli EA, Siempos II, Vardakas KZ. Acinetobacter infections: a growing threat for critically ill patients. Epidemiol Infect. 2008;136:1009-19.
4. Queenan AM, Pillar CM, Deane J, Sahm DF, Lynch AS, Flamm RK, et al. Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010. Diagn Microbiol Infect Dis. 2012;73:267-70.
5. Kempf M, Rolain JM. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int J Antimicrob Agents. 2012;39:105-14.
6. Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J, et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis. 2007;13:97-103.
7. Boyd N, Nailor MD. Combination antibiotic therapy for empiric and definitive treatment of Gram-negative infections: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2011;31:1073-84.
8. Pankuch GA, Seifert H, Appelbaum PC. Activity of doripenem with and without levofloxacin, amikacin, and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Diagn Microbiol Infect Dis. 2010;67:191-7.
9. Peterson J, Yektashenas B, Fisher A, Qin Z, Ketter N, Kaniga K, et al. Evaluation of the in vivo efficacy of doripenem or doripenem plus concomitant therapy for the treatment of pneumonia due to susceptible or non-susceptible Acinetobacter baumannii [abstract]. Am J Respir Crit Care Med. 2010;181: A3243.
10. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement. Document M100-S21. Wayne (PA): CLSI; 2011.
11. Pannek S, Higgins RG, Steinke P, Jonas D, Akova M, Bohnert JA, et al. Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-b-naphthylamide. J Antimicrob Chemother. 2006;57:970-4.
12. Vila J, Ruiz J, Goñi P, Marcos A, Jimenez de Anta T. Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother. 1995;39:1201-3.
13. Hamouda A, Amyes SG. Novel gyrA and parC point mutations in two strains of Acinetobacter baumannii resistant to ciprofloxacin. J Antimicrob Agents Chemother. 2004;54:695-6.
14. Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S, et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents. 2006;27:351-3.
15. Hu WS, Yao SM, Fung CP, Hsieh YP, Liu CP, Lin JF. An OXA- 66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. Antimicrob Agents Chemother. 2007;51:3844-52.
16. Seifert H, Dolzani L, Bressan R, van der Reijden T, van Strijen B, Stefanik D, et al. Standardization and interlaboratory reproducibility assessment of pulsed-field gel electrophoresisgenerated fingerprints of Acinetobacter baumannii. J Clin Microbiol. 2005;43:4328-35.
17. Clinical and Laboratory Standards Institute. Methods for determining bactericidal activity of antimicrobial agents; approved guideline. Document M26-A. Wayne (PA): CLSI; 1999.
18. Cirillo I, Vaccaro N, Turner K, Solanki B, Natarajan J, Redman R. Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers. J Clin Pharmacol. 2009;49:798-806.
19. Doribax® Prescribing Information 2007; revised 10/2010. Titusville (NJ): Ortho-McNeil-Janssen Pharmaceuticals, Inc. [cited 2012 Apr 16]. Available from: http://doribax.com/shared/ pi/doribax.pdf
20. Hori T, Nakano M, Kimura Y, Murakami K. Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. In Vivo. 2006;20:91-6.
21. LevaquinH Prescribing Information, revised Oct. 2011. Titusville (NJ): Janssen Pharmaceuticals, Inc. [cited 2012 Apr 16]. Available from: http://www.janssenmedicalinformation.com
22. Griffith DC, Corcoran E, Lofland D, Lee A, Cho D, Lomovskaya O, et al. Pharmacodynamics of levofloxacin against Pseudomonas aeruginosa with reduced susceptibility due to different efflux pumps: do elevated MICs always predict reduced in vivo efficacy? Antimicrob Agents Chemother. 2006;50:1628-32.
23. CiproH Prescribing Information, revised Sept. 2008. Wayne (NJ): Bayer HealthCare Pharmaceuticals Inc. [cited 2012 Apr 16]. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugL abelingChanges/ucm 121598.htm
24. Bédos JP, Azoulay-Dupuis E, Moine P, Muffat-Joly M, Veber B, Pocidalo JJ, et al. Pharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model: relevance for drug efficacy. J Pharmacol Exp Ther. 1998;286:29-35.
25. Rahal JJ. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis. 2006;43(Suppl 2):S95-9.
26. Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008;46:1254-63.
27. Pankuch GA, Lin G, Seifert H, Appelbaum PC. Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Antimicrob Agents Chemother. 2008;52:333-6.
28. Joly-Guillou ML, Wolff M, Farinotti R, Bryskier A, Carbon C. In vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia. J Antimicrob Chemother. 2000;46:827-30.
29. Miyasaki Y, Morgan MA, Chan RC, Nichols WS, Hujer KM, Bonomo RA, et al. In vitro activity of antibiotic combinations against multidrug-resistant strains of Acinetobacter baumannii and the effects of their antibiotic resistance determinants. FEMS Microbiol Lett. 2012;328:26-31.
30. Kiratisin P, Apisarnthanarak A, Kaewdaeng S. Synergistic activities between carbapenems and other antimicrobial agents against Acinetobacter baumannii including multidrug-resistant and extensively drug-resistant isolates. Int J Antimicrob Agents. 2010;36:243-6.